Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioequivalence Data: Statistical Interpretation01:16

Bioequivalence Data: Statistical Interpretation

117
Body:The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
117
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

126
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
126
Bioequivalence: Overview01:16

Bioequivalence: Overview

1.5K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.5K
Equivalence: In Vitro and In Vivo Bioequivalence01:17

Equivalence: In Vitro and In Vivo Bioequivalence

132
Body:Bioequivalence studies are crucial in evaluating whether new drugs can match an approved one regarding pharmacological effects and clinical performance. These studies test if drugs, despite different dosage forms, share identical plasma concentration-time profiles. Three types of equivalence are central to these studies: chemical, pharmaceutical, and therapeutic. Chemical equivalence indicates that two or more drug products contain identical active ingredients in equal amounts.
132
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

85
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
85
Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs01:15

Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs

100
Body:Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...
100

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Advancing quantitative clinical pharmacology competencies in Francophone Africa through an on-line learning framework.

Journal of pharmacokinetics and pharmacodynamics·2026
Same author

Plasma CXCL13 and fibrosis biomarkers in COVID-19 compared with idiopathic pulmonary fibrosis.

Scientific reports·2026
Same author

Construction of a tri-channel sensing array based on multimetal-doped CDs nanozymes for fingerprint pattern recognition of food antioxidants.

Food chemistry·2026
Same author

Portable ratiometric fluorescent sensor based on chiral carbon dots for accurate detection of L-arginine and N-acetylcysteine in commercial dietary supplements.

Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy·2026
Same author

A cross-sectional assessment of the quality and reliability of sleep disorder information on Douyin (TikTok in China).

Scientific reports·2026
Same author

High Nasopharyngeal SARS-CoV-2 Load and Delayed Clearance in Hospitalized Patients With Blood Autoantibodies Neutralizing Type I Interferons.

The Journal of infectious diseases·2026

Related Experiment Video

Updated: Dec 14, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.1K

Efficient model-based bioequivalence testing.

Kathrin Möllenhoff1, Florence Loingeville2, Julie Bertrand3

  • 1Department of Mathematics, Ruhr-Universität Bochum and Institute of Medical Statistics and Computational Biology, Faculty of Medicine, University of Cologne, Cologne, Germany.

Biostatistics (Oxford, England)
|July 23, 2020
PubMed
Summary
This summary is machine-generated.

A novel statistical test offers a more powerful approach to bioequivalence studies, improving pharmacokinetic analysis for drug formulations. This method provides more reliable results, especially for products with high variability, enhancing drug safety and efficacy assessments.

Keywords:
bioequivalencenoncompartmental bioequivalence analysisnonlinear mixed effects modelpharmacokineticstwo one-sided tests

More Related Videos

A Protocol for Using Gene Set Enrichment Analysis to Identify the Appropriate Animal Model for Translational Research
09:35

A Protocol for Using Gene Set Enrichment Analysis to Identify the Appropriate Animal Model for Translational Research

Published on: August 16, 2017

18.2K
Efficient Sampling of Genetically Encoded Biosensor Design Space Enabled with a Design of Experiments and Automation Workflow
08:58

Efficient Sampling of Genetically Encoded Biosensor Design Space Enabled with a Design of Experiments and Automation Workflow

Published on: October 17, 2025

410

Related Experiment Videos

Last Updated: Dec 14, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.1K
A Protocol for Using Gene Set Enrichment Analysis to Identify the Appropriate Animal Model for Translational Research
09:35

A Protocol for Using Gene Set Enrichment Analysis to Identify the Appropriate Animal Model for Translational Research

Published on: August 16, 2017

18.2K
Efficient Sampling of Genetically Encoded Biosensor Design Space Enabled with a Design of Experiments and Automation Workflow
08:58

Efficient Sampling of Genetically Encoded Biosensor Design Space Enabled with a Design of Experiments and Automation Workflow

Published on: October 17, 2025

410

Area of Science:

  • Pharmacokinetics
  • Biostatistics
  • Drug Development

Background:

  • Traditional bioequivalence studies use Non-Compartmental Analysis (NCA) and Two One-Sided Tests (TOST) to compare drug formulations based on pharmacokinetic parameters like Area Under the Curve (AUC) and maximum concentration (Cmax).
  • Current regulatory guidelines (FDA, EMA) require 90% confidence intervals for geometric mean ratios of AUC and Cmax to fall between 0.8 and 1.25 for bioequivalence.
  • NCA is unreliable for sparse pharmacokinetic data, necessitating model-based alternatives like nonlinear mixed effects models.

Purpose of the Study:

  • To propose a novel, more powerful statistical test for bioequivalence studies compared to the traditional TOST.
  • To evaluate the superiority of the proposed test through simulation studies.
  • To assess the test's performance for both NCA and model-based pharmacokinetic analyses.

Main Methods:

  • Development and simulation of a new statistical test for bioequivalence.
  • Comparison of the proposed test against the standard TOST method.
  • Evaluation across different pharmacokinetic data scenarios, including sparse designs and high variability.

Main Results:

  • The proposed test demonstrated superior power compared to TOST in simulation studies.
  • The new method exhibited Type I errors closer to the 0.05 significance level, particularly for products with high pharmacokinetic variability.
  • This suggests improved reliability over conventional methods in challenging bioequivalence scenarios.

Conclusions:

  • The novel statistical test offers a more robust and powerful alternative for bioequivalence analysis.
  • It shows particular promise for drug products exhibiting high variability in pharmacokinetic parameters.
  • This method could be valuable in situations where conventional bioequivalence analyses are insufficient or unreliable.